Cargando…

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice

BACKGROUND: The role of PPARα in gene regulation in mouse liver is well characterized. However, less is known about the role of PPARα in human liver. The aim of the present study was to better characterize the impact of PPARα activation on gene regulation in human liver. To that end, chimeric mice c...

Descripción completa

Detalles Bibliográficos
Autores principales:	de la Rosa Rodriguez, Montserrat A., Sugahara, Go, Hooiveld, Guido J. E. J., Ishida, Yuji, Tateno, Chise, Kersten, Sander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5991453/ https://www.ncbi.nlm.nih.gov/pubmed/29879903 http://dx.doi.org/10.1186/s12864-018-4834-3

Ejemplares similares

Humanized liver mouse model with transplanted human hepatocytes from patients with ornithine transcarbamylase deficiency
por: Sugahara, Go, et al.
Publicado: (2020)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human
por: Rakhshandehroo, Maryam, et al.
Publicado: (2009)

In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer
por: Saidi, Samir A, et al.
Publicado: (2006)

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
por: Bao, Wen, et al.
Publicado: (2021)

Estimating Drug Efficacy with a Diet-Induced NASH Model in Chimeric Mice with Humanized Livers
por: Kisoh, Keishi, et al.
Publicado: (2021)

The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia
por: Rolland, Benjamin, et al.
Publicado: (2012)

HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
por: Jia, Zhankui, et al.
Publicado: (2014)

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2016)

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism()()
por: Huang, Jianfeng, et al.
Publicado: (2013)

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2015)

PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
por: Liu, Tiantian, et al.
Publicado: (2023)

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
por: Stunes, Astrid K, et al.
Publicado: (2011)

A Human Hepatocyte-Bearing Mouse: An Animal Model to Predict Drug Metabolism and Effectiveness in Humans
por: Yoshizato, Katsutoshi, et al.
Publicado: (2009)

PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance
por: Liu, Jia, et al.
Publicado: (2016)

PPAR-α Agonist Fenofibrate Suppressed the Formation of Ocular Surface Squamous Metaplasia Induced by Topical Benzalkonium Chloride
por: He, Huan, et al.
Publicado: (2020)

Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice
por: Murru, Elisabetta, et al.
Publicado: (2022)

Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response
por: Chida, Takeshi, et al.
Publicado: (2023)

The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia
por: De Felice, Marta, et al.
Publicado: (2018)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study
por: Feng, Xiaomeng, et al.
Publicado: (2017)

Detection of acute toxicity of aflatoxin B1 to human hepatocytes in vitro and in vivo using chimeric mice with humanized livers
por: Ishida, Yuji, et al.
Publicado: (2020)

Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension
por: Li, Chuan-Bao, et al.
Publicado: (2009)

Culture density contributes to hepatic functions of fresh human hepatocytes isolated from chimeric mice with humanized livers: Novel, long-term, functional two-dimensional in vitro tool for developing new drugs
por: Yamasaki, Chihiro, et al.
Publicado: (2020)

L-carnitine and PPARα-agonist fenofibrate are involved in the regulation of Carnitine Acetyltransferase (CrAT) mRNA levels in murine liver cells
por: Kienesberger, Klemens, et al.
Publicado: (2014)

The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity
por: Nikam, Aniket, et al.
Publicado: (2018)

Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy
por: Abcouwer, Steven F.
Publicado: (2013)

Long‐term cell fate and functional maintenance of human hepatocyte through stepwise culture configuration
por: Sugahara, Go, et al.
Publicado: (2023)

An Integrated Statistical Approach to Compare Transcriptomics Data Across Experiments: A Case Study on the Identification of Candidate Target Genes of the Transcription Factor PPARα
por: Ullah, Mohammad Ohid, et al.
Publicado: (2012)

The Peroxisome Proliferator-Activated Receptor (PPAR) α Agonist Fenofibrate Suppresses Chemically Induced Lung Alveolar Proliferative Lesions in Male Obese Hyperlipidemic Mice
por: Kuno, Toshiya, et al.
Publicado: (2014)

PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice
por: Feng, Xiaomeng, et al.
Publicado: (2021)

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome–Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice
por: Guo, Xingyi, et al.
Publicado: (2022)

Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen
por: Baudi, Ian, et al.
Publicado: (2021)

PPAR-α Agonist Fenofibrate Upregulates Tetrahydrobiopterin Level through Increasing the Expression of Guanosine 5′-Triphosphate Cyclohydrolase-I in Human Umbilical Vein Endothelial Cells
por: Liu, Jinbo, et al.
Publicado: (2011)

Chimeric Mice with Humanized Livers: A Unique Tool for in Vivo and in Vitro Enzyme Induction Studies
por: Kakuni, Masakazu, et al.
Publicado: (2013)

Function of hepatocyte spheroids in bioactive microcapsules is enhanced by endogenous and exogenous hepatocyte growth factor
por: Gwon, Kihak, et al.
Publicado: (2023)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

PPARS and Obesity
por: Gregoire, Francine M., et al.
Publicado: (2007)

Fenofibrate suppresses corneal neovascularization by regulating lipid metabolism through PPARα signaling pathway
por: Zhou, Tong, et al.
Publicado: (2022)

Fenofibrate (a PPAR-α Agonist) Administered During Ethanol Withdrawal Reverts Ethanol-Induced Astrogliosis and Restores the Levels of Glutamate Transporter in Ethanol-Administered Adolescent Rats
por: Villavicencio-Tejo, Francisca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6bmfmct6vjurbg47rbioi8oh93